Moreover, CMP-001, a CpG DNA TLR9 agonist, was reported to have the ability to activate tumor-associated plasmacytoid dendritic cells to produce interferon, which in turn induces antitumor systemic immunity (37). The gene discussed is TLR9; the disease is neoplasm.